Yeo lab:Projects: Difference between revisions
No edit summary |
No edit summary |
||
Line 6: | Line 6: | ||
One of the major obstacles in translating potent drug candidates from bench to bedside is their spatiotemporally adequate delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. | One of the major obstacles in translating potent drug candidates from bench to bedside is their spatiotemporally adequate delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. | ||
'''Dr. Yeo’s lab''' will focus on developing drug/gene delivery systems which can address these challenges in ‘delivery.’ Specific research projects include: | |||
*Developing nanoparticles which mimic leukocyte-rolling behavior for tumor targeting. | |||
*Pulmonary drug delivery for cystic fibrosis and pulmonary hypertension therapy. | |||
*Developing sustained delivery systems for macromolecules based on hydrogels and novel microencapsulation techniques. | |||
|}<br style="clear:both" /> | |}<br style="clear:both" /> |
Revision as of 12:51, 14 January 2007
One of the major obstacles in translating potent drug candidates from bench to bedside is their spatiotemporally adequate delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. Dr. Yeo’s lab will focus on developing drug/gene delivery systems which can address these challenges in ‘delivery.’ Specific research projects include:
|